ArrowMark Colorado Holdings discloses 5.81% PMV Pharmaceuticals (PMVP) stake

Rhea-AI Filing Summary

ArrowMark Colorado Holdings, LLC filed an amended beneficial ownership report on PMV Pharmaceuticals, Inc. common stock. The firm reports beneficial ownership of 3,090,093 shares, representing 5.81% of the outstanding common stock as of the event date.

ArrowMark states it has sole voting and dispositive power over all reported shares and no shared power. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PMV Pharmaceuticals.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, par value $0.00001

(Title of Class of Securities)

69353Y103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

ArrowMark Colorado Holdings, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,090,093.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,090,093.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,090,093.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.81 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PMV Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON, NJ, 08540
Item 2.
(a)	Name of person filing: ArrowMark Colorado Holdings, LLC
(b)	Address or principal business office or, if none, residence: 100 Fillmore Street, Suite 325, Denver, Colorado 80206
(c)	Citizenship: Delaware, United States
(d)	Title of class of securities: Common stock, par value $0.00001
(e)	CUSIP No.: 69353Y103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,090,093
(b)	Percent of class: 5.81 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,090,093
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,090,093
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ArrowMark Colorado Holdings, LLC

Signature:	Richard Grove
Name/Title:	Richard Grove | Chief Compliance Officer
Date:	02/17/2026

FAQ

What stake does ArrowMark Colorado Holdings report in PMV Pharmaceuticals (PMVP)?

ArrowMark Colorado Holdings reports beneficial ownership of 3,090,093 PMV Pharmaceuticals common shares, representing 5.81% of the class. The position gives ArrowMark sole voting and dispositive power over all reported shares, according to the Schedule 13G/A filing.

Is ArrowMark Colorado Holdings a passive investor in PMV Pharmaceuticals (PMVP)?

ArrowMark certifies the PMV Pharmaceuticals shares were acquired and are held in the ordinary course of business. It states they were not acquired and are not held to change or influence control of the issuer, consistent with a passive investment stance under Schedule 13G.

How many PMV Pharmaceuticals (PMVP) shares can ArrowMark vote and dispose of?

ArrowMark reports sole power to vote and dispose of 3,090,093 PMV Pharmaceuticals common shares. It reports zero shared voting power and zero shared dispositive power, indicating full control over voting and disposition decisions for the reported holdings.

Why did ArrowMark file an amended Schedule 13G/A for PMV Pharmaceuticals (PMVP)?

The amended Schedule 13G/A updates ArrowMark’s beneficial ownership information for PMV Pharmaceuticals common stock as of December 31, 2025. It reflects a 5.81% stake and confirms the firm’s passive ownership intent and sole voting and dispositive power over the reported shares.

Who signed the ArrowMark Schedule 13G/A related to PMV Pharmaceuticals (PMVP)?

The Schedule 13G/A for ArrowMark’s PMV Pharmaceuticals holdings was signed by Richard Grove, Chief Compliance Officer. The signature certifies that, after reasonable inquiry, the information in the statement is true, complete and correct as of the stated date.